Can eculizumab be discontinued in aHUS?: Case report and review of the literature

BACKGROUND: The management of atypical hemolytic uremic syndrome (aHUS) has evolved into better control of thrombotic microangiopathy (TMA) and recovery of renal functions since the recent introduction of the terminal complement cascade blocker, eculizumab, into clinical use. Better characterization...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medicine (Baltimore)
Hauptverfasser: Sahutoglu, Tuncay, Basturk, Taner, Sakaci, Tamer, Koc, Yener, Ahbap, Elbis, Sevinc, Mustafa, Kara, Ekrem, Akgol, Cuneyt, Caglayan, Feyza Bayraktar, Unsal, Abdulkadir, Daha, Mohamed R.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Wolters Kluwer Health 2016
Schlagworte:
5200
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979790/
https://ncbi.nlm.nih.gov/pubmed/27495036
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000004330
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge